California-based Verrix builds momentum for commercialisation of its EVA Biological Indicator (BI) system and has announced the appointment of Kok-Hwee Ng and Aiying Sun as Vice President of R&D and VP of Regulatory & Quality, respectively.
The appointments follow on from the closing of nearly US$8 million fundraising round.
Dr Ng has more than two decades of leadership and management experience in the medical device industry, working with both startup and Fortune 500 companies such as St. Jude Medical, Stryker, Boston Scientific, Johnson & Johnson, Baxter International, General Electric Medical Systems, and OrthoSensor.
With more than 25 years of experience with medical device and pharmaceutical companies, Sun brings significant expertise in working closely with US and international regulatory authorities to establish and continuously improve quality management systems to ensure compliance with applicable regulations and standards.
For Verrix, both executives will help advance the company’s technology designed to protect patients from life-threatening infections.
Cameron Rouns, Verrix CEO, said Verrix is growing at a rapid pace as the company prepares for commercialisation of the EVA BI System. “We are excited to welcome Kok-Hwee and Aiying to the senior management group at this pivotal time for the company. Their extensive expertise, proven track record, and passion for emerging technology will be invaluable as we introduce our first-to-market platform and continue our pipeline development activities," he commented.
Verrix was founded in 2013 to develop sterility assurance products and technologies for the healthcare market and has doubled in size in the last year.
The company's foundational technology was originally invented and developed at NASA’s Jet Propulsion Laboratory. EVA BI System is expected to be introduced to the market in 2019.
